Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 52
Filter
1.
J Periodontal Res ; 51(4): 508-17, 2016 Aug.
Article in English | MEDLINE | ID: mdl-26548368

ABSTRACT

OBJECTIVES AND BACKGROUND: The involvement of DNA methylation in periodontal disease is not clear. Lipopolysaccharide (LPS) derived from Porphyromonas gingivalis is involved in the progression of periodontal disease. We recently developed an in vitro model of LPS infection in human periodontal fibroblast cells (HPdLFs) for a prolonged period. In this study, we examined genome-wide analysis of DNA methylation in HPdLFs stimulated with LPS derived from P. gingivalis for a prolonged period. We noted the hypermethylation of extracellular matrix (ECM)-related genes and examined whether hypermethylation affected their transcription levels. MATERIAL AND METHODS: HPdLFs were grown in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. The culture was repeated, alternating 3 d with LPS derived from P. gingivalis and 3 d without LPS for 1 mo. Untreated samples were used as controls. DNA was analyzed using the human CpG island microarray. Quantitative methylation-specific polymerase chain reaction was carried out to confirm reproducibility of the microarray data. The expression levels of mRNA of the selected ECM-related genes from the data were analyzed by quantitative reverse transcription-polymerase chain reaction. RESULTS: We found 25 ECM-related genes with hypermethylation at the CpG island of the promoter region, which exhibited a fourfold greater hypermethylation than controls. Among these genes, hypermethylation of nine ECM-related genes, FANK1, COL4A1-A2, 12A1 and 15A1, LAMA5 and B1, MMP25, POMT1 and EMILIN3, induced a significantly downregulated expression of their mRNA. CONCLUSION: These results indicate that LPS derived from P. gingivalis may cause DNA hypermethylation of some ECM-related genes followed by downregulated expression of their transcriptional levels.


Subject(s)
DNA Methylation , Extracellular Matrix/genetics , Fibroblasts/metabolism , Lipopolysaccharides/pharmacology , Porphyromonas gingivalis , Cells, Cultured , Down-Regulation , Extracellular Matrix/metabolism , Humans , Transcription, Genetic
2.
Eur J Vasc Endovasc Surg ; 49(5): 565-73, 2015 May.
Article in English | MEDLINE | ID: mdl-25747344

ABSTRACT

OBJECTIVES: Acceptable limb salvage rates underlie the widespread use of endovascular therapy (EVT) for patients with critical limb ischemia (CLI) secondary to isolated infrapopliteal lesions; however, post-EVT delayed wound healing remains a challenge. Predictors of delayed wound healing and their use in risk stratification of EVT in patients with CLI due to isolated infrapopliteal lesions are explored. METHODS: This was a retrospective multicenter study. 871 consecutive critically ischemic limbs were studied. There was tissue loss in 734 patients (age: 71 ± 10 years old; 71% male) who had undergone EVT between April 2004 and December 2012. The wound healing rate after EVT was estimated by the Kaplan-Meier method. The association between baseline characteristics and delayed wound healing was assessed by the Cox proportional hazard model. RESULTS: Diabetes mellitus and regular dialysis were present in 75% (553/734) and 64% (476/734) of patients, respectively; 67% of limbs (585/871) had Rutherford class 5 CLI; 8% (67/871) of wounds were located in the heel only; 25% (219/871) of limbs had Rutherford 6 (involving not only the heel); and 42% (354/871) of wounds were complicated by infection. The rate of freedom from major amputation at 1 year reached 88%, whereas the wound healing rate was 67%. Median time to wound healing was 146 days. By multivariate analysis, non-ambulatory status (hazard ratio [HR], 1.58; 95% confidence interval [CI] 1.31-1.91) serum albumin <3 g/dL (HR 1.42; 95% CI 1.08-1.86), Rutherford 6 (not only heel) (HR 1.68; 95% CI 1.33-2.14), wound infection (HR 1.24; 95% CI 1.03-1.50), EVT not based on angiosome concept (HR 1.28; 95% CI 1.06-1.55), and below the ankle (BTA) 0 vessel runoff after EVT (HR 1.45; 95% CI 1.14-1.86) were independent predictors of delayed wound healing. CONCLUSIONS: Non-ambulatory status, low albumin level, Rutherford 6 (not only heel), wound infection, indirect intervention, and poor BTA runoff were independent predictors for delayed wound healing after EVT in patients with CLI secondary to infrapopliteal lesions, and their use in risk stratification allows estimation of the wound healing rate.


Subject(s)
Diabetes Mellitus/epidemiology , Ischemia/epidemiology , Limb Salvage , Lower Extremity/surgery , Renal Dialysis/statistics & numerical data , Wound Healing , Adult , Aged , Aged, 80 and over , Female , Humans , Ischemia/surgery , Limb Salvage/methods , Lower Extremity/blood supply , Male , Middle Aged , Prevalence , Retrospective Studies , Risk Factors , Treatment Outcome , Wound Healing/physiology
3.
Lupus ; 18(12): 1108-11, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19762388

ABSTRACT

Gelatinous transformation of the bone marrow is a rare disease characterised by a focal marrow hypoplasia, fat atrophy and accumulation of extracellular mucopolysaccharides abundant in hyaluronic acid, which is often associated with extreme malnutrition and weight loss. There are only two reports describing its association with systemic lupus erythematosus (SLE). One described underlying diseases in 155 cases of gelatinous transformation of the bone marrow and found one case with clinical diagnosis of SLE, but no clinical details were provided. The other described three SLE patients with gelatinous transformation of the bone marrow; however, two of these were cachectic and one was diagnosed with concomitant tuberculosis. We describe one active SLE patient without other comorbidities whose pancytopaenia was histologically confirmed as gelatinous transformation. The combination of high-dose steroid, intravenous immunoglobulin and mycophenolate mofetil improved the peripheral blood cytopaenia and reversed the bone marrow abnormalities.


Subject(s)
Bone Marrow Diseases/etiology , Bone Marrow Diseases/pathology , Bone Marrow/pathology , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/pathology , Anti-Inflammatory Agents/therapeutic use , Biopsy , Bone Marrow Diseases/drug therapy , Female , Glycosaminoglycans/metabolism , Humans , Hyaluronic Acid/metabolism , Immunoglobulins, Intravenous/therapeutic use , Immunosuppressive Agents/therapeutic use , Lupus Erythematosus, Systemic/drug therapy , Methylprednisolone/therapeutic use , Middle Aged , Mycophenolic Acid/analogs & derivatives , Mycophenolic Acid/therapeutic use
4.
Biochem Biophys Res Commun ; 284(3): 650-4, 2001 Jun 15.
Article in English | MEDLINE | ID: mdl-11396950

ABSTRACT

A mass screening program for congenital hypothyroidism has markedly improved prognosis of children with congenital hypothyroidism and also revealed several cases with unknown pathogenesis. We here report two independent Japanese multigeneration families with multinodular goiter (MNG) with euthyroidism and with high TSH. The propositi, 3- and 8-year-old girls in two families, were found during a mass screening. An autosomal dominant pattern of inheritance was suggested in both families. The clinical examinations suggested impaired hormonogenesis but discarded known defects in iodine transport, organification, deficiency of hydrogen peroxide, and thyroid peroxidase. Linkage analysis of the two families including 10 members each using 343 microsatellite markers mapped a single locus independently at D3S1618 (theta = 0) on 3q26.1-q26.3 with a two-point LOD score 3.62 (1.81 for each family) and multipoint LOD score of 3.61 (1.80 for each family). Haplotype inspection delimited an 18-cM interval between D3S1565 and D3S3686.


Subject(s)
Chromosomes, Human, Pair 3 , Goiter, Nodular/genetics , Adult , Child , Child, Preschool , Chromosome Mapping , Female , Goiter, Nodular/pathology , Humans , Male , Pedigree , Thyroid Gland/pathology
5.
Hinyokika Kiyo ; 43(5): 333-7, 1997 May.
Article in Japanese | MEDLINE | ID: mdl-9208316

ABSTRACT

We previously reported that Takusya had the inhibitory effect on in vitro calcium oxalate crystallization and in vivo stone formation in an animal model and it could be a prophylactic agent against calcium oxalate stone formation. We studied the effect of Takusya on calcium oxalate crystallization in human urine. Takusya (500 mg/day and 1,000 mg/day) was administered to 16 healthy men for 3 days and then 24-hour urine samples were collected to measure the urinary excretion of calcium, phosphate, magnesium, uric acid, creatinine, citric acid and oxalic acid. The urine samples before the administration of Takusya was used as a control. The size and distribution of crystals, which were formed in the urine samples by adding calcium chloride and sodium oxalate, were measured using the Coulter counter technique. Urinary magnesium excretion was significantly reduced by 1,000 mg/day of Takusya compared with the control (p < 0.05). The growth of crystals was significantly inhibited by 500 mg/day of Takusya in the large crystal formers whose urine created crystals more than 3.5 microns before the administration of Takusya (p < 0.05). These findings suggested that Takusya inhibited the growth of crystals formed in human urine.


Subject(s)
Calcium Oxalate/urine , Drugs, Chinese Herbal/pharmacology , Administration, Oral , Adult , Crystallization , Drugs, Chinese Herbal/administration & dosage , Humans , Magnesium/urine , Male , Urinary Calculi/prevention & control
6.
Nihon Jinzo Gakkai Shi ; 39(2): 129-34, 1997 Mar.
Article in Japanese | MEDLINE | ID: mdl-9134829

ABSTRACT

This study was undertaken to evaluate destructive spondylarthropathy (DSA) in patients long-term dialysis. The patients were investigated by plain X-ray examinations twice with a three-year interval, and the changes in severity of the illness in 66 patients undergoing dialysis for over 5 years were defined. Group A (9 patients) consisted of patients with progression in grades during the three years, while group B (57 patients) consisted of patients without deterioration. There was no differences in the two groups in age, duration and the modality of dialysis. However, in group A, the level of plasma beta 2-microglobulin (beta 2M) was 33.5 +/- 14.6 micrograms/ml at the first observation, and 33.1 +/- 15.1 micrograms/ml at the second (NS). In group B, the level of plasma beta 2M was 45.6 +/- 8.13 micrograms/ml at the first observation, and 39.7 +/- 9.18 micrograms/ml at the second (p <0.05). No improvement in DSA was observed. The result of this study suggests that DSA will not improve once it has become overt, and the management for lowering the level of beta 2M may prevent the occurrence and progression of DSA.


Subject(s)
Renal Dialysis/adverse effects , Spondylitis, Ankylosing/pathology , Adult , Aged , Arthrography , Blood Urea Nitrogen , Female , Humans , Male , Middle Aged , Spondylitis, Ankylosing/blood , Spondylitis, Ankylosing/diagnostic imaging , beta 2-Microglobulin/analysis
7.
Urol Res ; 25(5): 355-60, 1997.
Article in English | MEDLINE | ID: mdl-9373917

ABSTRACT

We previously extracted crystal surface binding substance (CSBS) from human urine and showed that it appeared to constitute a substantial proportion of urinary macromolecular inhibitors of calcium oxalate crystallization. CSBS was isolated from human urine and fractionated by three consecutive chromatography procedures in order to characterize protein inhibitors of calcium oxalate crystallization. Sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and NH2-terminal amino acid sequencing revealed that inhibitory fractions eluted from a final, hydroxyapatite column contained prothrombin and osteopontin. Hydroxyapatite column fractions also contained other, unidentified protein inhibitors of calcium oxalate crystallization. CSBS contained also human serum albumin, alpha 1-acid glycoprotein, alpha 1-microglobulin, alpha 2-HS glycoprotein, retinol-binding protein, transferrin, and Tamm-Horsfall protein, but these proteins seemed to play no direct role in inhibitory activity.


Subject(s)
Glycoproteins/urine , Adult , Amino Acid Sequence , Calcium Oxalate/antagonists & inhibitors , Calcium Oxalate/metabolism , Chromatography , Crystallization , Electrophoresis, Polyacrylamide Gel , Glycoproteins/chemistry , Glycoproteins/physiology , Humans , Male , Osteopontin , Prothrombin/analysis , Sialoglycoproteins/analysis
8.
Nihon Jinzo Gakkai Shi ; 38(4): 155-63, 1996 Apr.
Article in Japanese | MEDLINE | ID: mdl-8709414

ABSTRACT

Coronary atherosclerosis and calcification score were assessed angiographically in 30 uremic patients receiving dialysis (8 patients with diabetes mellitus [DM dialysis group] and 22 patients without DM [non-DM dialysis group] who were suspected of having coronary artery disease because of their clinical symptoms and electrocardiographic findings. Thirty non-uremic subjects (11 with DM and 19 without DM) served as controls. Twelve dialysis patients (40%) did not have significant coronary artery disease, and the rate of significant coronary artery disease in dialysis patients overall was less than that in the control subjects. The calcification score of dialysis patients was significantly higher than that of the control patients (P < 0.0001), and also scores of the non-DM dialysis group and the DM dialysis group were higher than those of each group of control subjects. The scores were significantly correlated with the duration of dialysis in uremic patients as a group (r = 0.52; P < 0.01) and the non-DM dialysis group (r = 0.70; P < 0.01), but were not correlated with the duration of dialysis in the DM dialysis group. The scores were correlated with serum phosphate concentration, but not with serum calcium concentration, calcium phosphate product, alkaline phosphatase levels total cholesterol or age. Calcification scores were extremely high (> 21) in six uremic patients who had high serum c-terminal parathyroid hormone concentrations. These findings indicate that serum phosphate concentration, serum c-terminal parathyroid hormone concentration, and the duration of dialysis are closely associated with coronary calcification in long-term dialysis patients.


Subject(s)
Calcinosis/etiology , Coronary Artery Disease/etiology , Coronary Disease/etiology , Renal Dialysis/adverse effects , Adult , Aged , Calcinosis/diagnostic imaging , Coronary Angiography , Coronary Artery Disease/diagnostic imaging , Coronary Disease/diagnostic imaging , Diabetic Nephropathies/complications , Female , Humans , Kidney Failure, Chronic/complications , Male , Middle Aged , Parathyroid Hormone/blood , Phosphates/blood , Risk Factors , Time Factors
9.
Hinyokika Kiyo ; 41(6): 427-31, 1995 Jun.
Article in Japanese | MEDLINE | ID: mdl-7645450

ABSTRACT

We examined the inhibitory effect of the two Kampo medicines, takusha and kagosou on the formation of calcium oxalate renal stones induced by ethylene glycol (EG) and 1 alpha(OH)D3 (1 alpha-D3) in rats. Wistar strain rats were divided into 4 groups (A: normal control, B: stone, C: kagosou, D: takusya). There was no significant difference in urinary calcium excretion or oxalate excretion between the stone group and kampo medicine groups. The calcium content of the kidneys was significantly lower in the takusha group than in the other two groups (Stone group and kagosou group). Takusha was effective in preventing oxalate stone formation in rats. Kagosou, which had strong inhibitory effect on calcium oxalate crystal growth and aggregation in vitro as well as takusha, was not effective against in vivo calcium oxalate stone formation in rats. These findings suggest that takusha prevents the formation of calcium oxalate stone by inhibiting calcium oxalate crystal growth and aggregation.


Subject(s)
Calcium Oxalate/metabolism , Drugs, Chinese Herbal/therapeutic use , Kidney Calculi/prevention & control , Animals , Crystallization , Drugs, Chinese Herbal/pharmacology , Kidney Calculi/chemistry , Male , Rats , Rats, Wistar
10.
Int J Urol ; 2(2): 81-6, 1995 May.
Article in English | MEDLINE | ID: mdl-7553293

ABSTRACT

Kampou medicine is a traditional Japanese therapeutic system which originated in China and was used to treat various diseases for hundreds of years until it was superseded by Western medicine. In recent years, there has been a resurgence of interest in Kampou medicine among many physicians. Unfortunately, however, little evaluation has been performed using objective scientific methods until now, and the pharmacodynamics of Kampou medicine are still unclear. Generally speaking, Kampou medicine has been shown to have fewer side-effects than Western medicine based on the experience gained from its long usage. We first selected 16 Kampou extracts for screening as possible calcium oxalate stone prophylactic agents in vitro. This resulted in the selection of two kinds of Kampou extracts, Takusya and Kagosou, as potential Kampou extracts for stone prophylaxis. Next, these two Kampou extracts were tested in vivo for their effects on stone formation in an animal model. Takusya showed significant stone prophylaxis, while Kagosou did not. Lastly, Chorei-to, which contains Takusya and has been approved for prescription as a Kampou medicine for urolithiasis patients in Japan, was examined in vivo at two different concentrations. As a result, a low dose of Chorei-to which corresponded to the human daily dose per unit of body weight exhibited apparent stone prophylaxis, despite the disadvantage of decreasing citrate excretion. In contrast, high doses of Chorei-to did not exhibit stone prophylaxis in vivo.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Calcium Oxalate/metabolism , Drugs, Chinese Herbal/pharmacology , Kidney Calculi/drug therapy , Medicine, Chinese Traditional , Animals , Coloring Agents , Crystallization , Disease Models, Animal , Dose-Response Relationship, Drug , Glycosaminoglycans/analysis , Kidney Calculi/chemistry , Kidney Calculi/prevention & control , Male , Plants, Medicinal , Rats , Rats, Wistar , Sulfates/analysis
11.
Nihon Jinzo Gakkai Shi ; 37(3): 172-8, 1995 Mar.
Article in Japanese | MEDLINE | ID: mdl-7731105

ABSTRACT

We investigated factors affecting net transperitoneal calcium balance (Ca-BL) and the level of parathyroid hormone in relation to stepwise changes in serum calcium, by short PET (peritoneal equibrium test during 240 min: using 2000 ml of 2.5% dextrose dialysate containing 1.75 mmol/L Ca) in uremic patients undergoing stable CAPD. We calculated Ca-BL (mg/effluent/PET) of 244 effluents obtained from 90 patients receiving calcium carbonate as a phosphate binder without vitamin D supplementation. Their serum calcium level corrected with albumin (cSCa), alkaline phosphatase activity (ALP) and intact-PTH level was 9.7 +/- 0.9 mg/dl, 236 +/- 83 mIU/ml and 153.0 +/- 172.4 pg/ml, respectively. We proposed two statistic significant regression lines between Ca-BL and total drainage effluent volume (Ca-BL = 133X - 0.056: r = 0.981, P < 0.001), cSCa (Ca-BL = -12.9X + 123.6: r = 0.941, P < 0.01). Total drainage volume (TDV) and cSCa were two major factors affecting Ca-BL. A TDV level of 2430 ml/240 min-PET or more was required for positive Ca-BL in cases with 9.5-10.0 mg/dl of cSCa, using this linear regression analysis. A cSCa level of 9.6 mg/dl or more was also required for positive Ca-BL in cases with 2400-2600 ml/240min-PET. We also proposed a significant linear regression line between the intact-PTH level and cSCa (i-PTH = -90.5X + 1015.8, r = 0.973, P < 0.01). This line suggest that 200 pg/ml of intact PTH was obtained by 9.0 mg/dl or less of cSCa level in 90 CAPD uremic patients.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Calcium/administration & dosage , Dialysis Solutions/chemistry , Hypoparathyroidism/etiology , Peritoneal Dialysis, Continuous Ambulatory/adverse effects , Adult , Calcium/metabolism , Female , Humans , Hypoparathyroidism/prevention & control , Male , Middle Aged , Peritoneum/metabolism , Regression Analysis
12.
Miner Electrolyte Metab ; 21(1-3): 67-71, 1995.
Article in English | MEDLINE | ID: mdl-7565465

ABSTRACT

The effects of parathyroidectomy on left ventricular muscle volume and mechanical performance were evaluated echocardiographically in 24 patients with secondary hyperparathyroidism due to chronic renal failure and in 7 with primary hyperparathyroidism. Intraventricular septum and posterior wall thickness, left ventricular end-diastolic diameters, shortening fraction, ejection fraction, and left ventricular mass index were measured by M mode recording by the parasternal short axis view prior to parathyroidectomy as baseline and repeated 12 months after parathyroidectomy. Serum basal carboxyterminal parathyroid hormone levels in patients with secondary hyperparathyroidism (34.4 +/- 13.7 ng/ml) were significantly higher than in those with primary hyperparathyroidism (3.4 +/- 5.1 ng/ml; p < 0.0001). At 12 months after parathyroidectomy, intraventricular septum and posterior wall thickness, left ventricular end-diastolic diameter and left ventricular mass index were reduced from 11.8 +/- 3.1 mm, 10.9 +/- 1.7 mm, 53.8 +/- 6.3 mm, 200.8 +/- 57.1 g/m2 to 10.0 +/- 2.1 mm (p < 0.05), 9.8 +/- 1.9 mm (p < 0.05), 50.7 +/- 7.2 mm (p < 0.05), 149.6 +/- 38.7 g/m2 (p < 0.0001), in patients with secondary hyperparathyroidism. In patients with primary hyperparathyroidism, all echocardiographic parameters remained in the normal range and did not show any significant changes before or after parathyroidectomy. From this study, parathyroid hormone at extremely high concentrations as seen in secondary hyperparathyroidism appears to be a cardiotoxic substance. Therefore, all patients with secondary hyperthyroidism should be examined by echocardiography and parathyroidectomy should be considered if myocardial hypertrophy is present.


Subject(s)
Hyperparathyroidism, Secondary/surgery , Hypertrophy, Left Ventricular/etiology , Parathyroidectomy , Adult , Aged , Case-Control Studies , Female , Follow-Up Studies , Humans , Hyperparathyroidism, Secondary/complications , Male , Middle Aged
13.
Urol Res ; 21(3): 187-92, 1993 May.
Article in English | MEDLINE | ID: mdl-8342253

ABSTRACT

The nature of the soluble stone matrix and its possible role in urinary stone formation was studied. For this purpose we performed two-dimensional cellulose acetate membrane electrophoresis of the glycosaminoglycans (GAGs) which were contained in the soluble stone matrix, substances adsorbed onto calcium oxalate crystals in vitro (crystal surface binding substances, CSBS) and urinary macromolecules (UMMs). The main GAG in the soluble stone matrix and CSBS was found to be heparan sulfate, whereas the UMMs contained various GAGs usually seen in urine. An inhibition assay showed the soluble stone matrix to have the strongest inhibitory activity among these macromolecular substances when inhibitory activity was expressed in terms of uronic acid concentration. It is suggested that the main GAG in the soluble stone matrix consists of heparan sulfate, which has a strong inhibitory activity on calcium oxalate crystal growth and aggregation and constitutes part of the CSBS.


Subject(s)
Calcium Oxalate/chemistry , Heparitin Sulfate/metabolism , Urinary Calculi/metabolism , Adult , Crystallization , Electrophoresis, Cellulose Acetate , Heparitin Sulfate/pharmacology , Heparitin Sulfate/physiology , Humans , Macromolecular Substances , Male , Solubility , Urine/chemistry
14.
Br J Urol ; 71(5): 516-22, 1993 May.
Article in English | MEDLINE | ID: mdl-8518855

ABSTRACT

We investigated the influence of ionic strength on both the binding ability of macromolecules onto calcium oxalate crystals and the inhibitory activity of macromolecules related to calcium oxalate crystal growth and aggregation in vitro. The amount of heparin sodium salt adsorbed onto calcium oxalate crystals was studied in both a seed and a non-seed crystal system at various ionic strengths with the aid of radiolabelled heparin. In both adsorption models, adsorption of heparin was greater in the buffered solutions of lower ionic strength, and significantly so in the range of physiological ionic strength. The inhibitory activity of heparin in the non-seed crystal system, which was determined using a Coulter Multisizer, increased as the adsorbed dose increased. The naturally existing urinary macromolecules showed a similar change in their inhibitory activity on calcium oxalate crystal growth and/or aggregation in accordance with changes in ionic strength. These results indicate that macromolecular inhibitory activity seems to be enhanced in urine of lower ionic strength as a result of an increased adsorption of macromolecules on the surface of calcium oxalate crystals.


Subject(s)
Calcium Oxalate/pharmacokinetics , Heparin/pharmacokinetics , Adsorption , Adult , Humans , Macromolecular Substances , Male , Osmolar Concentration , Urine
15.
Kaku Igaku ; 30(4): 363-9, 1993 Apr.
Article in Japanese | MEDLINE | ID: mdl-8315886

ABSTRACT

To evaluate the left ventricular early diastolic function after dipyridamole infusion or during exercise, the first pass radionuclide angiocardiography (FPRA) by a multicrystal gamma camera (SIM-400) was performed in 32 patients with coronary artery disease (CAD) and 14 normal subjects. Dipyridamole was administered intravenously (0.56 mg/kg in 4 min). The first third filling fraction (FF 1/3) and the first third mean filling rate (MFR 1/3) were calculated from the time-activity curve. FF 1/3 decreased and MFR 1/3 increased in both normal subjects and patients with CAD during exercise. After dipyridamole infusion, FF 1/3 and MFR 1/3 unchanged in normal subjects, in contrast, FF 1/3 and MFR 1/3 decreased in patients with CAD. Thus, dipyridamole infusion FPRA is more sensitive method to detect early diastolic dysfunction in patients with CAD than FPRA during exercise.


Subject(s)
Coronary Disease/diagnosis , Diastole , Dipyridamole , Exercise Test , Ventricular Function, Left , Ventriculography, First-Pass , Aged , Coronary Disease/physiopathology , Female , Humans , Male , Middle Aged
16.
Nihon Hinyokika Gakkai Zasshi ; 84(4): 674-9, 1993 Apr.
Article in Japanese | MEDLINE | ID: mdl-8492511

ABSTRACT

Alkali therapy is widely accepted as a treatment for recurrent calcium stone patients with distal renal tubular acidosis (dRTA). Nine patients, five with complete and four with incomplete type of dRTA, were treated with alkali agents for more than three years; an average period of 10.8 years. In five patients, new stone formation and stone growth were completely prevented by this treatment. Among the four failed cases, three did not take enough alkali agents (in spite of our medication), and the other had recurrent urinary tract infection resulting in infectious stone formation. In conclusion, the long-term efficacy of alkali therapy for prevention of recurrent stone formation with dRTA is confirmed when the patient takes enough alkali agents and the urinary tract infection is well controlled.


Subject(s)
Acidosis, Renal Tubular/complications , Calcium/urine , Citrates/administration & dosage , Kidney Calculi/drug therapy , Adult , Citrates/therapeutic use , Female , Humans , Kidney Calculi/complications , Kidney Calculi/urine , Kidney Tubules, Distal , Male , Middle Aged , Recurrence
17.
Br J Urol ; 70(4): 399-403, 1992 Oct.
Article in English | MEDLINE | ID: mdl-1450848

ABSTRACT

Between March 1981 and March 1990, 15 patients with locally advanced transitional cell carcinoma of the bladder were treated concurrently with cisplatin and radiotherapy. Treatment comprised a radiation dose of 40-50 Gy in 20-25 fractions over 4-5 weeks and intravenous infusion of cisplatin with hydration during days 1-5 and 22-26. The total scheduled dose of cisplatin was 200 mg. A complete response (CR) was seen in 3 patients (2 T2 tumours and 1 T3) and the other 12 were regarded as partial responders. Two of the 12 partial responders (1 T2 tumour and 1 T4) underwent cystectomy after treatment, but 9 patients (2 T2, 6 T3 and 1 T4) underwent only transurethral resection. The remaining patient (with a T4 tumour) died from systemic disease, further treatment not being possible because of unrelated heart failure. In 3 CR patients and 9 with a partial response (PR), bladder function was preserved and they have survived for a mean of 18.3 months (range 5-47) after therapy. Although 4 patients in this group had recurrent bladder tumours and 1 died from cancer in another part of the body, 7 have survived with normal bladder function and no recurrence. It is concluded that concurrent cisplatin and radiation therapy is a safe and viable regimen and may be considered as a means of preserving the bladder in patients with locally advanced transitional cell carcinoma.


Subject(s)
Carcinoma, Transitional Cell/drug therapy , Carcinoma, Transitional Cell/radiotherapy , Cisplatin/therapeutic use , Urinary Bladder Neoplasms/drug therapy , Urinary Bladder Neoplasms/radiotherapy , Aged , Carcinoma, Transitional Cell/surgery , Cisplatin/adverse effects , Combined Modality Therapy , Cystectomy , Female , Humans , Male , Middle Aged , Urinary Bladder/surgery , Urinary Bladder Neoplasms/surgery
18.
Prosthet Orthot Int ; 16(2): 104-8, 1992 Aug.
Article in English | MEDLINE | ID: mdl-1408667

ABSTRACT

A plastic ankle foot orthosis (AFO) was developed, referred to as functional ankle foot orthosis Type 2 (FAFO (II)), which can deal with genu recurvatum and the severe spastic foot in walking. Clinical trials were successful for all varus and drop feet, and for most cases of genu recurvatum. Electromyogram studies showed that the FAFO (II) reduced the spasticity of gastrocnemius and hamstring muscles and activated the quadricep muscles. Gait analysis revealed a reduction of the knee angles in the stance phase on the affected side when using the FAFO (II). Mechanical stress tests showed excellent durability of the orthosis and demonstrated its effectiveness for controlling spasticity in comparison with other types of plastic AFOs.


Subject(s)
Cerebrovascular Disorders/complications , Foot Deformities, Acquired/rehabilitation , Knee Joint/abnormalities , Muscle Spasticity/rehabilitation , Orthotic Devices/standards , Spinal Diseases/complications , Adolescent , Adult , Aged , Biomechanical Phenomena , Child , Electromyography , Female , Foot Deformities, Acquired/diagnosis , Foot Deformities, Acquired/etiology , Gait , Humans , Male , Middle Aged , Muscle Spasticity/diagnosis , Muscle Spasticity/etiology
19.
FEBS Lett ; 302(2): 129-32, 1992 May 11.
Article in English | MEDLINE | ID: mdl-1633844

ABSTRACT

The N- and O-linked oligosaccharides in a yeast-derived HBsAg M protein (pre-S2 + S) were analyzed. Two major structures of the N-linked oligosaccharides bound to residue Asn4 were determined to be high-mannose type oligosaccharides, Man7GlcNAc2 and Man8GlcNAc2, by two-dimensional sugar mapping of the corresponding pyridylamino oligosaccharides. Peptide mapping of the M protein, sequence analysis of the glycopeptides after beta-elimination under reducing conditions and sugar-composition analysis revealed that the O-linked oligosaccharides were composed solely of mannose and bound to residue Ser5, Thr6, Thr7, Ser27, Ser28, Ser29 and Thr31 in the pre-S2 region.


Subject(s)
Hepatitis B Surface Antigens/analysis , Oligosaccharides/analysis , Saccharomyces cerevisiae/chemistry , Amino Acid Sequence , Carbohydrate Conformation , Carbohydrate Sequence , Hepatitis B Surface Antigens/chemistry , Mannose/analysis , Molecular Sequence Data , Oligosaccharides/chemistry , Recombinant Proteins/analysis , Recombinant Proteins/chemistry , Saccharomyces cerevisiae/metabolism
20.
Hinyokika Kiyo ; 38(3): 311-4, 1992 Mar.
Article in English | MEDLINE | ID: mdl-1523986

ABSTRACT

A 72-year-old woman with bilateral non-Hodgkin's lymphoma of the adrenal glands causing adrenal insufficiency is reported. The left-side lymphoma (diffuse large B-cell lymphoma) was removed surgically but the right-side lymphoma could not be removed. Complete response was obtained with subsequent combined chemotherapy and was maintained for 6 months with repeated chemotherapies. However, the patient died of liver recurrence 1 year after admission. In cases of malignant lymphoma forming a bulky mass, surgery with subsequent chemotherapy appears to reduce the cancer volume and improve the therapeutic outcome.


Subject(s)
Adrenal Gland Neoplasms/complications , Adrenal Insufficiency/etiology , Lymphoma, B-Cell/complications , Lymphoma, Large B-Cell, Diffuse/complications , Adrenal Gland Neoplasms/drug therapy , Adrenal Gland Neoplasms/surgery , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Etoposide/administration & dosage , Female , Humans , Lymphoma, B-Cell/drug therapy , Lymphoma, B-Cell/surgery , Lymphoma, Large B-Cell, Diffuse/drug therapy , Lymphoma, Large B-Cell, Diffuse/surgery , Prednisolone/administration & dosage , Remission Induction , Vincristine/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL